A vs BDSX
A: A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical diagnostics laboratories worldwide. BDSX: Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and biopharmaceutical companies.
Side-by-side fundamentals
| Metric | A | BDSX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $137.89 | $22.22 | |
| Market cap as of 2026-07-31 | $38.9B | $221M | |
| P/E as of 2026-07-31 | 27.58 | n/a | |
| PEG as of 2026-07-31 | 3.24 | n/a | |
| Net margin as of 2026-07-31 | +19.6% | -33.3% | A higher |
| Gross margin as of 2026-07-31 | +52.9% | +82.1% | BDSX higher |
| Operating margin as of 2026-07-31 | +21.5% | -25.9% | A higher |
| ROE as of 2026-07-31 | +20.8% | -375.1% | A higher |
| ROA as of 2026-07-31 | +11.1% | -35.6% | A higher |
| Debt / equity as of 2026-07-31 | 0.47 | 5.09 | A lower |
| Revenue growth (YoY) as of 2026-07-31 | +9.1% | +29.1% | BDSX higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +32.3% | BDSX higher |
| Dividend yield as of 2026-07-31 | +0.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-31 | 1.23 | 0.59 | |
| 1-year return as of 2026-07-27 close | +14.7% | +149.1% | BDSX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.